PVCT - Provectus Biopharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0759
+0.0069 (+10.0000%)
At close: 3:52PM EST
Stock chart is not supported by your current browser
Previous Close0.0690
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume1,035,509
Market Cap28.139M
Beta0.81
PE Ratio (TTM)N/A
EPS (TTM)-0.0490
Earnings DateMar 31, 2017 - Apr 3, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    FIRST STUDY OF QUALITY OF LIFE OF PATIENTS WITH LOCALLY ADVANCED CUTANEOUS MELANOMA PUBLISHED IN MELANOMA RESEARCH

    Emotional health/self-perception issues were most common; limitations of lifestyle and activities as well as coping strategies were also important Provectus Biopharmaceuticals expands pivotal Phase 3 trial ...

  • GlobeNewswire2 months ago

    PROVECTUS BIOPHARMACEUTICALS RECEIVES THIRD CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE

    –Protection expands coverage for combinations of intralesional PV-10 with checkpoint inhibitors for multiple solid tumor cancers–. KNOXVILLE, TN, Dec. 14, 2017-- Provectus Biopharmaceuticals, Inc., a clinical-stage ...

  • GlobeNewswire2 months ago

    PROVECTUS Announces Resolution of SEC Investigation

    –SEC“ takes into account the proactive remediation and cooperation by the ompany’ s new leadership”–. –No monetary penalties; Commission notes actions already taken by Provectus to remedy internal controls–. ...

  • GlobeNewswire3 months ago

    PROVECTUS ANNOUNCES RESULTS FROM MECHANISM OF ACTION STUDY OF TOPICAL PH-10 FOR THE TREATMENT OF PSORIASIS

    –Responses mediated by multiple pathways, including IL-17, IL-22 and interferons–. –Down-regulation of more than 500 disease-related genes; wide range of central“ psoriasis-related” genes effectively normalized–. ...

  • Provectus Biopharmaceuticals Reestablishes Strategic Advisory Board
    PR Newswire10 months ago

    Provectus Biopharmaceuticals Reestablishes Strategic Advisory Board

    KNOXVILLE, Tenn., April 20, 2017 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) ("Provectus" or the "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, today announced the reestablishment of the Company's Strategic Advisory Board (the "SAB"). Initial SAB appointees are John W. 'Jack' Lacey III, M.D., and Ed Pershing as SAB Chairman. Provectus today also announced Mr. Pershing was appointed an observer (serving exclusively in an advisory capacity only) of the Company's board of directors (the "Board"), and Bruce Horowitz was retained as Provectus' chief operations consultant.

  • Provectus Biopharmaceuticals Closes Definitive Financing With PRH Group
    PR Newswire11 months ago

    Provectus Biopharmaceuticals Closes Definitive Financing With PRH Group

    KNOXVILLE, Tenn., April 4, 2017 /PRNewswire/ --  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ("Provectus" or the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ...

  • PR Newswire11 months ago

    Provectus Biopharmaceuticals Announces Terms Of Definitive Financing Commitment

    KNOXVILLE, Tenn., March 23, 2017 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com ) ("Provectus" or the "Company"), a clinical-stage oncology and ...

  • Provectus Biopharmaceuticals Enters Into Definitive Financing Commitment Term Sheet
    PR Newswire11 months ago

    Provectus Biopharmaceuticals Enters Into Definitive Financing Commitment Term Sheet

    KNOXVILLE, Tenn., March 20, 2017 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) ("Provectus" or the "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, today announced that on March 19 it entered into an exclusive Definitive Financing Commitment Term Sheet with a group of the Company's stockholders (Group B) related to a previously submitted unsolicited proposal (Proposal B). The Company previously had received two unsolicited proposals relating to potential equity financings (individually, "Proposal A" and "Proposal B" and collectively, the "Proposals") from two separate groups of the Company's stockholders (in each case, "Group A" and "Group B").  Consistent with its fiduciary duties, the board of directors (the "Board") carefully reviewed and considered both Proposals, and rejected Proposal A because the financial terms of Proposal A were determined to be detrimental to the future of the Company as an ongoing concern, significantly benefitted Group A investors at the expense of the Company's existing stockholders, and because Proposal A imposed other requirements, including proposed management members and compensation, that the Board believed were not in the best interests of the Company and the Company's stockholders.

  • Provectus Biopharmaceuticals, Inc. Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In Provectus
    PR Newswirelast year

    Provectus Biopharmaceuticals, Inc. Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In Provectus

    KNOXVILLE, Tenn., March 6, 2017 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com ) ("Provectus" or the "Company"), a clinical-stage oncology and ...

  • PR Newswirelast year

    Provectus Biopharmaceuticals Provides Information On Rights Offering Deadline

    KNOXVILLE, Tenn., Feb. 24, 2017 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) ("Provectus" or the "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, today is providing additional information regarding the deadline to participate in its previously announced rights offering of up to 19 million units, consisting of shares of common stock and Series C Convertible Preferred Stock to existing stockholders and holders of listed warrants. As previously announced, the rights offering will remain open until 5 pm Eastern Time on March 3, 2017. However, if rights holders are exercising subscription rights through a broker, dealer, bank or other nominee, they should promptly contact their nominee and submit subscription documents and payment for the units subscribed for in accordance with the instructions and within the time period provided by such nominee.

  • PR Newswirelast year

    Provectus Biopharmaceuticals Appoints Bruce Horowitz And Dominic Rodrigues As Special Advisers To The Board Of Directors

    KNOXVILLE, Tenn., Feb. 23, 2017 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (PVCT) (www.provectusbio.com) ("Provectus" or the "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, today announced that it has appointed Bruce Horowitz and Dominic Rodrigues as special advisers to the Company's Board of Directors.  Mr. Horowitz and Mr. Rodrigues will advise the board on financial and corporate strategy.